Cargando…

PATH-06. Molecular subgrouping of medulloblastoma via low-depth whole genome bisulfite sequencing

INTRODUCTION: International consensus recognises four molecular subgroups of medulloblastoma, each with distinct molecular features and clinical outcomes. Assigning molecular subgroup is typically achieved via the Illumina DNA methylation microarray. Given the rapidly-expanding WGS capacity in healt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Dean, Castle, Jemma, Hicks, Debbie, Schwalbe, Ed, Clifford, Steve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Pathology/Classification
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165418/ http://dx.doi.org/10.1093/neuonc/noac079.590

Ejemplares similares

OMIC-06. MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA VIA LOW-DEPTH WHOLE GENOME BISULFITE SEQUENCING
por: Thompson, Dean, et al.
Publicado: (2021)

PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study
por: Delaidelli, Alberto, et al.
Publicado: (2022)

PATH-07. Diagnostic and therapeutic value of cerebrospinal fluid biopsy in pediatric brain tumors
por: Li, Shaoqun, et al.
Publicado: (2022)

PATH-01. Infant-Type Hemispheric Glioma: New Molecular Alterations and Precision-Medicine Treatment
por: Hu, Wanming, et al.
Publicado: (2022)

PATH-04. Array-based global DNA Methylation profiling of mouse brain tumors allows comparison to human tumors
por: Schoof, Melanie, et al.
Publicado: (2022)

PATH-05 Challenge and clinical relevance of a non-matching classifier output in genome-wide DNA methylation analysis for CNS neoplasms in pediatric and adolescent patients
por: Drexler, Richard, et al.
Publicado: (2022)

PATH-02. Using DNA methylation profiling to define tumor type and appropriate treatment: a case report and review of the literature of a rare CNS CIC altered sarcoma
por: Brodwater, William, et al.
Publicado: (2022)

Classifying retinopathy of prematurity
por: Molinari, Andrea, et al.
Publicado: (2017)

Classification and staging of retinoblastoma
por: Fabian, Ido Didi, et al.
Publicado: (2018)

The AO Pediatric Comprehensive Classification of Long Bone Fractures (PCCF): Part I: Location and morphology of 2,292 upper extremity fractures in children and adolescents
por: Joeris, Alexander, et al.
Publicado: (2017)

The AO Pediatric Comprehensive Classification of Long Bone Fractures (PCCF): Part II: Location and morphology of 548 lower extremity fractures in children and adolescents
por: Joeris, Alexander, et al.
Publicado: (2017)

The AO Pediatric Comprehensive Classification of Long Bone Fractures (PCCF): Part III: Multifragmentary long bone fractures in children—a retrospective analysis of 2,716 patients from 2 tertiary pediatric hospitals in Switzerland
por: Audigé, Laurent, et al.
Publicado: (2017)

EMBR-25. GENOME-WIDE GENETIC AND EPIGENETIC ASSESSMENT OF GROUP 4 MEDULLOBLASTOMA FOR IMPROVED, BIOMARKER DRIVEN, PROGNOSTICATION AND RISK-STRATIFICATION
por: Goddard, Jack, et al.
Publicado: (2021)

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study
por: Schwalbe, Edward C, et al.
Publicado: (2017)

PATH-06. IMAGE-BASED MACHINE LEARNING CLASSIFIER FOR PEDIATRIC POSTERIOR FOSSA TUMOR HISTOPATHOLOGY
por: Tam, Lydia, et al.
Publicado: (2020)

Ethnic boxes: the unintended consequences of Habsburg bureaucratic classification
por: Stergar, Rok, et al.
Publicado: (2018)

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
por: Sharma, Tanvi, et al.
Publicado: (2019)

Molecular subgroups of medulloblastoma: the current consensus
por: Taylor, Michael D., et al.
Publicado: (2011)

Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance
por: Lindsey, Janet C., et al.
Publicado: (2014)

Current medulloblastoma subgroup specific clinical trials
por: Thompson, Eric M., et al.
Publicado: (2020)

MEDB-31. THE CLINICAL SIGNIFICANCE OF EXTENT OF RESECTION IN MEDULLOBLASTOMA
por: Keeling, Claire, et al.
Publicado: (2022)

Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development
por: Williamson, Daniel, et al.
Publicado: (2022)

Xanthogranulomatous Pyelonephritis and Its Differential Diagnoses: An In-Depth Case Review
por: Herrera-Bedoya, María, et al.
Publicado: (2021)

MEDB-71. Molecular characterisation of group 4 medulloblastoma improves risk-stratification and its biological understanding
por: Goddard, Jack, et al.
Publicado: (2022)

MEDB-65. Molecular subclassification of a national cohort of pediatric medulloblastoma based on methylation profile
por: Alaña, Lide, et al.
Publicado: (2022)

Squamous Cell Carcinoma of the Sigmoid Colon: A Path Less Traveled
por: Ramachandra, Deepti, et al.
Publicado: (2022)

PATH-09. SJMB12 CLINICAL TRIAL: DISCREPANCY BETWEEN LOCAL AND CENTRAL PATHOLOGY IN ASSESSING ANAPLASTIC MEDULLOBLASTOMA – REPORT FROM A SINGLE SITE EXPERIENCE
por: Khuong-Quang, Dong-Anh, et al.
Publicado: (2020)

PATH-07. QUALITY ASSURANCE IN CEREBROSPINAL FLUID CYTOLOGY ASSESSMENT FOR MEDULLOBLASTOMA STAGING LEADS TO POTENTIAL IMPROVED RISK-GROUP ASSESSMENT IN THE PROSPECTIVE MULTICENTER HIT-2000 TRIAL
por: Hagel, Christian, et al.
Publicado: (2020)

PD-L1 expression in medulloblastoma: an evaluation by subgroup
por: Martin, Allison M., et al.
Publicado: (2018)

Deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray
por: Hacking, James P.R., et al.
Publicado: (2023)

The Path of Most Resistance: A Rare Instance of Metastatic Pancreatic Adenocarcinoma Identified Within Skeletal Muscle
por: Harmon, Caitlin E, et al.
Publicado: (2021)

Phosphatase and Tensin Homolog (PTEN) Expression as a Surrogate Biomarker Correlated With the Depth of Invasion in Cutaneous Malignant Melanoma
por: Sun, Ziyi, et al.
Publicado: (2023)

QOL-06. QUALITY OF LIFE IN MEDULLOBLASTOMA SURVIVORS IN WESTERN MEXICO
por: del Campo, Regina M Navarro-Martin, et al.
Publicado: (2020)

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
por: Goschzik, Tobias, et al.
Publicado: (2018)

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
por: Goddard, Jack, et al.
Publicado: (2023)

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial
por: Clifford, Steven C., et al.
Publicado: (2015)

Common Florida angiosperm families.
por: Zomlefer, Wendy B., 1954-
Publicado: (1983)

PATH-17. INTRAGENIC COPY NUMBER BREAKPOINT ANALYSIS OF METHYLATION DATA FROM CNS TUMOURS IDENTIFIES NOVEL SUBGROUP-SPECIFIC CANDIDATE FUSION GENE ENRICHMENTS
por: Mackay, Alan, et al.
Publicado: (2020)

Novel mutations target distinct subgroups of medulloblastoma
por: Robinson, Giles, et al.
Publicado: (2012)

Subgroup-specific roles of primary cilia in medulloblastoma
por: Marino, Silvia
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u8mm8iuhhdhbvqntc36p4dqve8